Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Significantly increased risk of all-cause mortality among cardiac patients feeling lonely

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Role of the lymphatic vasculature in cardiovascular medicine

    Research output: Contribution to journalReviewResearchpeer-review

  4. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Clinical implications of electrocardiographic bundle branch block in primary care

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Performance of Prognostic Risk Scores in Heart Failure Patients: Do Sex Differences Exist?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Transcatheter Aortic Valve Replacement: Role of Multimodality Imaging in Common and Complex Clinical Scenarios

    Research output: Contribution to journalReviewResearchpeer-review

  3. Uafklaret dyspnø.

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: The optimal timing for transplantation is unclear in patients with Eisenmenger syndrome (ES). We investigated post-transplantation survival and transplantation-specific morbidity after heart-lung transplantation (HLTx) or lung transplantation (LTx) in a cohort of Nordic patients with ES to aid decision-making for scheduling transplantation.

METHODS: We performed a retrospective, descriptive, population-based study of patients with ES who underwent transplantation from 1985 to 2012.

RESULTS: Among 714 patients with ES in the Nordic region, 63 (9%) underwent transplantation. The median age at transplantation was 31.9 (IQR 21.1-42.3) years. Within 30 days after transplantation, seven patients (11%) died. The median survival was 12.0 (95% CI 7.6 to 16.4) years and the overall 1-year, 5-year, 10-year and 15-year survival rates were 84.1%, 69.7%, 55.8% and 40.6%, respectively. For patients alive 1 year post-transplantation, the median conditional survival was 14.8 years (95% CI 8.0 to 21.8), with 5-year, 10-year and 15-year survival rates of 83.3%, 67.2% and 50.0%, respectively. There was no difference in median survival after HLTx (n=57) and LTx (n=6) (14.9 vs 10.6 years, p=0.718). Median cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis/kidney transplantation-free survival rates were 11.2 (95% CI 7.8 to 14.6), 6.9 (95% CI 2.6 to 11.1) and 11.2 (95% CI 8.8 to 13.7) years, respectively. The leading causes of death after the perioperative period were infection (36.7%), bronchiolitis obliterans syndrome (23.3%) and heart failure (13.3%).

CONCLUSIONS: This study shows that satisfactory post-transplantation survival, comparable with contemporary HTx and LTx data, without severe comorbidities such as cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis, is achievable in patients with ES, with a conditional survival of nearly 15 years.

Original languageEnglish
JournalHeart (British Cardiac Society)
Volume106
Issue number2
Pages (from-to)127-132
ISSN1355-6037
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • Eisenmenger syndrome, heart-lung transplantation, lung transplantation

ID: 58015496